Nonmotor symptoms in Parkinson's disease

International Journal of Neuroscience

Volumn 121, Issue SUPPL. 2, 2011, Pages 9-17

  Stacy, Mark ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Impulse control disorder; Nonmotor; Parkinson; Psychosis

Indexed keywords

AKATHISIA; ANXIETY; APATHY; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN STEM; CONSTIPATION; DEMENTIA; DEPRESSION; HUMAN; IMPULSE CONTROL DISORDER; MILD COGNITIVE IMPAIRMENT; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PSYCHOSIS; RESTLESSNESS; SENSORY DYSFUNCTION; SLEEP DISORDER; SPINAL CORD; SYMPTOM;

AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; HUMANS; MENTAL DISORDERS; MOOD DISORDERS; PARKINSON DISEASE;

EID: 80155142256     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.620196     Document Type: Article

References (96)

1. Jankovic J. Parkinsons disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76. (Pubitemid 351441488)
2. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinsons disease. J Neural Transm. 2008;115:443-60
3. Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G. Pain and motor complications in Parkinsons disease. J Neurol Neurosurg Psychiatry. 2006;77:822-5. (Pubitemid 44023175)
4. Aarsland D, Tandberg E, Largsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol. 1996;53:538-42. (Pubitemid 26177134)
5. Biggins CA, Boyd JL, Harrop FA, Madeley P, Mindham RH, Randall JI, Spokes EG. A controlled, longitudinal study of dementia in Parkinsons disease. J Neurol Neurosurg Psychiatry 1992;55:566-72.
6. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017-22. (Pubitemid 351451309)
7. Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU. Cognitive impairment in 873 patients with idiopathic Parkinsons disease. Results from the German Study on Epidemiology of Parkinsons Disease with Dementia (GEPAD). J Neurol. 2008;255:255-64.
8. Reid WG, HelyMA, Morris JG, Loy C, Halliday GM. Dementia in Parkinsons disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry. 2011;82:1033-7.
9. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinsons disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-44.
10. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow W, PoeweW, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinsons disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22:2314-24. (Pubitemid 351155975)
11. Tr öster AI. Neuropsychological characteristics of Dementia with Lewy Bodies and Parkinsons disease with dementia: differentiation, early detection, and implications for Mild Cognitive Impairment and biomarkers. Neuropsychol Rev. 2008;18:103-19.
12. Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinsons disease. Parkinsons Dis. 2011 Feb 17;2011:708404.
13. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinsons disease Acta Neuropathol. 2008;115:409-15.
14. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinsons disease. N Engl J Med. 2004;351:2509-18. (Pubitemid 39603164)
15. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinsons disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 May 3. doi: 1002/mds.23697. Epub ahead of print.
16. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinsons disease: a randomized controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708-12. (Pubitemid 34557010)
17. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinsons disease. Int J Geriatr Psychiatry. 2004;19:1-8. (Pubitemid 38180686)
18. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T. Donepezil for dementia in Parkinsons disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934-9. (Pubitemid 40909549)
19. PoeweW,Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R; EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinsons disease: an active treatment extension study. Mov Disord. 2006;21:456-61.
20. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:1654-6. (Pubitemid 41689487)
21. Gurevich TY, Shabtai H, Korczyn AD, Simon ES, Giladi N. Effect of rivastigmine on tremor in patients with Parkinsons disease and dementia. Mov Disord. 2006;21:1663-6. (Pubitemid 44742195)
22. Wilkinson DG, Passmore AP, Bullock R, van Baelen B, Schwalen S. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimers disease. Int J Clin Pract. 2002;56:441-6. (Pubitemid 34855303)
23. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008 Feb;62(2): 149-53.
24. Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinsons disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763-6.
25. Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R,Wittchen HU. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinsons disease. J Neurol. 2010;257(7):1073-82.
26. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinsons disease. Neurology. 1995;45:669-71.
27. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinsons disease. Neurology. 1993;43:2227-9. (Pubitemid 23346953)
28. Ravina B, Marder K, Fernandez HH, Friedman JH,McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C. Diagnostic criteria for psychosis in Parkinsons disease: report of an NIND, NIMH work group. Mov Disord. 2007;22:1061-8. (Pubitemid 47067214)
29. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of benign hallucinations in Parkinsons Disease. Arch Neurol. 2006;63(5):713-6.
30. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998;51:811-4. (Pubitemid 28449264)
31. Kiziltan G, Ozekmekçi S, Ertan S, Ertan T, Erginöz E. Relationship between age and subtypes of psychotic symptoms in Parkinsons disease. J Neurol. 2007;254(4):448-52. (Pubitemid 46786718)
32. Stacy M. Managing late complications of Parkinsons disease. Med Clin N Am. 1999;83:469-81. (Pubitemid 29120024)
33. Weintraub D, Hurtig HI: Presentation and management of psychosis in Parkinsons disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164:1491-8. (Pubitemid 350069725)
34. Stacy M. Recognizing and treating nonmotor symptoms in Parkinsons disease. CNS Spectrums. 1998;3:41-5. (Pubitemid 29122710)
35. Zahodne LB, Fernandez HH. Parkinsons psychosis. Curr Treat Options Neurol. 2010;12:200-11.
36. The Parkinsons disease study group. Low-dose clozapine for the treatment of durg-induced psychosis in Parkinsons disease. N Engl J Med. 1999;340(10):757-63.
37. Pollak P, Tison F, Rascol O, Destée A, Péré JJ, Senard JM,Durif F, Bourdeix I. Clozapine in drug induced psychosis in Parkinsons disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-95. (Pubitemid 38526677)
38. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Raterblinded, prospective comparison: quetiapine versus clozapine for Parkinsons disease psychosis. Clin Neuropharmacol. 2006;29(6):331-7. (Pubitemid 44729944)
39. Klein C, Prokhorov T, Miniovich A,Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. 2006 Jul-Aug;29(4):215-9. (Pubitemid 44510458)
40. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010;26(2):111-5.
41. Ferrara JM, StacyM. Impulse control disorders and Parkinsons disease. CNS Spectrums. 2008;13:690-8.
42. Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, Caporali A, Mancini F, Pezzoli G, Ceravolo R, Bonuccelli U, Barone P. Impulsivity and compulsivity in drug-naive patients with Parkinsons disease. Mov Disord. 2011;26:464-8.
43. Galpern WR, Stacy M. Management of impulse control disorders in Parkinsons disease. Curr Treat Options Neurol. 2007;9:189-97. (Pubitemid 46736341)
44. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, Pelissolo A, Moro E, Lhommée E, Lang AE, Agid Y, Benabid AL, Pollak P, Mallet L, Krack P. Pathological gambling in Parkinsons disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006 Nov;21(11): 1941-6. (Pubitemid 44848942)
45. Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinsons disease. Mov Disord. 2008;23:183-9. (Pubitemid 351311545)
46. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL. Neuropsychiatric symptoms in patients with Parkinsons disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78:36-42. (Pubitemid 46048261)
47. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002. (Pubitemid 44044781)
48. Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV. Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study. Mov Disord. 2007;22:2037-42.
49. Antonini A, Colosimo C, Marconi R, Morgante L, Barone P; PRIAMO studygroup. The PRIAMO study: background, methods and recruitment. Neurol Sci. 2008;29(2):61-5. (Pubitemid 351696406)
50. DellAngnello G, Ceravalo R, Nuti A, Bellini G, Piccinni A, DAvino C, DellOsso L, Bonuccelli U. SSRIs do not worsen Parkinsons disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24:221-7. (Pubitemid 32717856)
51. Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinsons disease: a systematic review. Drugs. 2011;71:273-86.
52. StacyM, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, Lewitt P, Oertel W, Quinn N, Sethi K, Stocchi F. Identification of motor and non-motor wearing-off in Parkinsons disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726-33. (Pubitemid 41051784)
53. Stacy M, Hauser R, Wearing Off Study Group. Development of a wearing-off patient questionnaire to facilitate recognition of the motor and non-motor symptoms of wearingoff in Parkinsons disease. J Neural Transm. 2007;114: 211-7. (Pubitemid 46147158)
54. Borek LL, Amick MM, Friedman JH, Non-motor aspects of Parkinsons disease. CNS Spectr. 2006;11:541-54.
55. Varanese S, Perfetti B, Ghilardi MF, Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinsons disease. PLoS One. 2011 Mar 18;6(3):e17846.
56. Stacy, M. Sleep disorders in Parkinsons disease: epidemiology and management. Drugs Aging. 2002;19:733-9. (Pubitemid 35305832)
57. Van Hilten B, Hoff JI, Huub AM. Sleep disruption in Parkinsons disease. Arch Neurol. 1995;51:922-8.
58. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol. 1982;5:183-94. (Pubitemid 13209012)
59. Verban D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep problems and daytime sleepiness in Parkinsons disease. Mov Disord. 2008;23:35-41. (Pubitemid 351281215)
60. Comella CL, Tanner CM, Ristanovic RL. Polysomnographic sleep measures in Parkinsons disease patients with treatment induced hallucinations. Ann Neurol. 1993;34:710-4. (Pubitemid 23333244)
61. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-10. (Pubitemid 29260911)
62. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole induced somnolence and sleep episodes of daytime sleep. Mov Disord. 2000;15:658-63. (Pubitemid 30479617)
63. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinsons disease. Mov Disord. 2003;18:287-93. (Pubitemid 36410825)
64. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinsons disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76:1636-9. (Pubitemid 41697625)
65. Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, PardiD. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65:1337-40.
66. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007;69:333-41. (Pubitemid 47205659)
67. Edwards L, Quigley EM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinsons disease: an 18-month follow-up study. Mov Disord. 1993;8:83-6. (Pubitemid 23039236)
68. Wullner U, Schmitz-Hubsch T, Antony G, Fimmersa R, Spottkea A, Oertel WH, Deuschl G, Klockgether T, Eggert K; on behalf of the KNP. Autonomic dysfunction in 3414 Parkinsons disease patients enrolled in the German Network on Parkinsons disease: the effect of aging. Eur J Neurol. 2007;14:1405-8. (Pubitemid 350135306)
69. Mathers SE, Kempster PA, Law PJ, Frankel JP, Bartram CI, Lees AJ, Stern GM, Swash M. Anal sphincter dysfunction in Parkinsons disease. Arch Neurol. 1989;46:1061-4. (Pubitemid 19246293)
70. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord. 2008;23:1065-75.
71. Fitzmaurice H, Fowler CJ, Rickards D, Kirby RS, Quinn NP, Marsden CD, Milroy EJG, Turner-Warwick RT. Micturition disturbance in Parkinsons disease. Br J Urol. 1985;57:652-6.
72. Ransmayr GN, Holliger S, Schletterer K, Heidler H, Deibl M, Poewe W, Madersbacher H, Kiss G. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinsons disease and Alzheimer disease. Neurology. 2008;70:299-303. (Pubitemid 351156810)
73. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinsons disease. Mov Disord. 2010;25:2-12.
74. Bronner G, Royter V, Korczyn AD, Gilaldi N. Sexual dysfunction in Parkinsons disease. J Sex Marital Ther. 2004;30:95-105.
75. Kaufmann H. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl. 2006;(70):477-84. (Pubitemid 44622240)
76. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinsons disease andmultiple system atrophy. Mov Disord. 2001;16:1176-7. (Pubitemid 36041238)
77. Degen L, Petrig C, Studer D, Schroller S, Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil. 2005;17:821-6. (Pubitemid 41746520)
78. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinsons disease. Mov Disord. 2006;21:115-6. (Pubitemid 43273764)
79. Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C. Macrogol for the treatment of constipation in Parkinsons disease. A randomized placebo-controlledstudy. Mov Disord. 2007;22:1239-44. (Pubitemid 47325029)
80. Kapoor S. Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol. 2008;14(33):5226-7.
81. Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agro E. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68:1455-9. (Pubitemid 46685914)
82. Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005;21:71-80. (Pubitemid 40327507)
83. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786-99. (Pubitemid 38209648)
84. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinsons disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71:371-4. (Pubitemid 32772536)
85. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907-13. (Pubitemid 43970109)
86. Biousse V, Skibell BC,Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinsons disease. Neurology. 2004;62:177-80.
87. Sartucci F, Orlandi G, Lucetti C, Bonuccelli U, Murri L, Orsini C, Porciatti V. Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinsons disease. J Clin Neurophysiol. 2003;20:375-81. (Pubitemid 38031212)
88. Rascol O, Clanet M, Montastruc JL, Simonetta M, Soulier-Esteve MJ, Doyon B, Rascol A. Abnormal ocular movements in Parkinsons disease: evidence for involvement of dopaminergic systems. Brain. 1989;112:1193-214. (Pubitemid 19246373)
89. Hood AJ, Amador SC, Cain AE, Briand KA, Al-Refai AH, Schiess MC, Sereno AB. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinsons disease. J Neurol Neurosurg Psychiatry. 2007;78:565-70. (Pubitemid 46853888)
90. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinsons disease. Vision Res. 2005;45:1285-96. (Pubitemid 40331887)
91. Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008;14:253-4.
92. Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, Moretto G, Abbruzzese G, Marchese R, Bonuccelli U, Del Dotto P, Barone P, De Vivo E, Albanese A, Antonini A, Canesi M, Lopiano L, Zibetti M, Nappi G, Martignoni E, Lamberti P, Tinazzi M. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65:1191-4.
93. Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O; DoPaMiP Study Group. Chronic pain in Parkinsons disease: the cross-sectional French DoPaMiP survey.Mov Disord, 2008: 23: 1361-9.
94. Schestatsky P, KumruH, Valls-Solé J, Valldeoriola F,Marti MJ, Tolosa E, Chaves ML. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69:2162-9. (Pubitemid 350294696)
95. Ondo WG, Vuong DK, Jankovic J. Exploring the relationship between Parkinsons disease and restless legs syndrome. Arch Neurol. 2002;59:421-4. (Pubitemid 34208151)
96. Gomez-Esteban JC, Zarranz JJ, Tijero B, Zarranz JJ, González C, Bilbao G, Lambarri I, Rodríguez O, Garibi J. Restless legs syndrome in Parkinsons disease. MovDisord. 2007;22:1912-6. (Pubitemid 350134204)